Table 3.
Gender-expansive and gender-affirming therapy percentages
| Gender-expansive | Gender-affirming therapy | |
|---|---|---|
| Sexual orientation/gender identity (SOGI) field pattern, n (%) | ||
| Gender identity: transgender female (N = 359) | 358 (99.7%) | 321 (89.4%) |
| Gender identity: transgender male (N = 519) | 517 (99.6%) | 454 (87.5%) |
| Gender identity: nonbinary (N = 553) | 552 (99.8%) | 142 (25.7%) |
| Gender identity: female, different from other fields (N = 296) | 273 (92.2%) | 246 (83.1%) |
| Gender identity: male, different from other fields (N = 306) | 284 (92.8%) | 246 (80.4%) |
| Gender identity: other (N = 100) | 79 (79.0%) | 28 (28.0%) |
| Gender identity: choose not to disclose (N = 141) | 28 (19.9%) | 18 (12.8%) |
| All other SOGI field differences (N = 24) | 6 (25.0%) | 6 (25.0%) |
| All patients with SOGI field differences (N = 2298) | 2097 (91.3%) | 1461 (63.6%) |
| Diagnostic code search, n (%) | ||
| ICD-10 codes related to gender dysphoria (N = 1553) | 1550 (99.8%) | 1217 (78.4%) |
| ICD-10 code E34.9 (N = 1480) | 1408 (95.1%) | 1295 (87.5%) |
| Any of the above ICD-10 codes (N = 1891) | 1817 (96.1%) | 1455 (76.9%) |
| SOGI field difference and/or ICD-10 codes related to gender dysphoria (N = 2422) | 2219 (91.6%) | 1500 (61.9%) |
| Prescription for estradiol or testosterone suggesting use of gender-affirming hormones, n (%) (N = 1292) | 1171 (90.6%) | 1155 (89.4%) |
| Estradiol medication with legal sex of male (N = 483) | 482 (99.8%) | 479 (99.2%) |
| Testosterone medication with legal sex of female (N = 809) | 689 (85.2%) | 676 (83.6%) |
| Estradiol medication with cisgender male SOGI pattern (N = 16) | 14 (87.5%) | 14 (87.5%) |
| Testosterone medication with cisgender female SOGI pattern (N = 137) | 17 (12.4%) | 17 (12.5%) |
Abbreviation: ICD-10: International Statistical Classification of Diseases and Related Health Problems, 10th Revision codes and medication